Genmab A/S (NASDAQ:GMAB) Raised to “Strong-Buy” at Truist Financial

Genmab A/S (NASDAQ:GMAB) was upgraded by stock analysts at Truist Financial to a “strong-buy” rating in a note issued to investors on Wednesday,Zacks.com reports.

A number of other brokerages have also recently issued reports on GMAB. Morgan Stanley assumed coverage on shares of Genmab A/S in a research report on Monday, February 16th. They set an “equal weight” rating and a $34.00 target price for the company. HC Wainwright increased their price target on shares of Genmab A/S from $39.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday, February 18th. Guggenheim dropped their price objective on shares of Genmab A/S from $45.00 to $40.00 and set a “buy” rating for the company in a research note on Monday, February 23rd. Wells Fargo & Company assumed coverage on Genmab A/S in a research report on Monday, March 2nd. They set an “overweight” rating and a $40.00 price objective for the company. Finally, Wall Street Zen lowered Genmab A/S from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $40.58.

Genmab A/S Stock Down 0.3%

Genmab A/S stock opened at $26.03 on Wednesday. Genmab A/S has a fifty-two week low of $17.24 and a fifty-two week high of $35.43. The firm has a market capitalization of $16.72 billion, a price-to-earnings ratio of 16.79, a price-to-earnings-growth ratio of 1.07 and a beta of 0.94. The stock’s fifty day moving average is $29.53 and its two-hundred day moving average is $30.46. The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.01 and a current ratio of 2.02.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings results on Tuesday, February 17th. The company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.46 by ($0.41). Genmab A/S had a return on equity of 17.35% and a net margin of 25.89%.The firm had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.06 billion. Analysts predict that Genmab A/S will post 1.45 EPS for the current fiscal year.

Hedge Funds Weigh In On Genmab A/S

Institutional investors have recently modified their holdings of the company. Paradigm Biocapital Advisors LP acquired a new stake in Genmab A/S during the third quarter worth approximately $117,063,000. Orbis Allan Gray Ltd grew its stake in Genmab A/S by 30.2% in the 4th quarter. Orbis Allan Gray Ltd now owns 14,418,462 shares of the company’s stock worth $444,089,000 after acquiring an additional 3,340,456 shares during the period. Arrowstreet Capital Limited Partnership raised its holdings in Genmab A/S by 152.3% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 3,454,378 shares of the company’s stock valued at $71,367,000 after acquiring an additional 2,084,966 shares during the last quarter. Pictet Asset Management Holding SA purchased a new position in shares of Genmab A/S during the 4th quarter worth $33,835,000. Finally, Perpetual Ltd purchased a new position in shares of Genmab A/S during the 4th quarter worth $25,478,000. Institutional investors and hedge funds own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.